Tag:
Jeremy Levin
Latest Headlines
Latest Headlines
Analysts question Teva's blockbuster expectations on drug makeovers
Teva's new CEO, Jeremy Levin, has been touting the company's plan to come up with a pipeline of late-stage drugs that take well-known medicines and give them a makeover for new uses.
Israeli officials put the tax squeeze on Teva
The company didn't make any friends in Israel when local media reported tiny tax rates paid by the company. Coming as they did amid news of cost-cutting and layoffs, the tax figures stung--and sparked a public outcry, Haaretz notes. And now, Israeli Finance Minister Yair Lapid is in talks with Teva chief Jeremy Levin to work out a settlement.
Teva CEO plans to court Chinese market with generics, respiratory meds
Teva CEO Jeremy Levin thinks his company and China are a match made in heaven. The Israeli generics giant is, after all, adept at making and selling cheap drugs, which the fast-growing Chinese market needs. And Teva has a strong portfolio of respiratory treatments--perfect for a country beset by air pollution.
U.S. Judge lashes out at FDA over its Plan B maneuver
Teva Pharmaceutical Industries' hot potato contraceptive drug Plan B One Step is getting tossed around some more, as a U.S. federal judge labeled the U.S government's position on it "intellectually dishonest."
Amid $2B in cost-cutting, Teva sales suffer from generic erosion
Teva Pharmaceutical Industries may be a generics behemoth, but its earnings this quarter bore a more-than-casual resemblance to Big Pharma's.
Teva whacking U.S. plant as it squeezes hard on costs
Teva Pharmaceutical Industries is in the midst of devising a master plan to downsize its manufacturing network as CEO Jeremy Levin looks to carve $2 billion in annual costs out of the generics maker.
Teva hikes dividend as earnings fall short
If Teva Pharmaceutical Industries investors are ticked off about its shortfall in fourth-quarter earnings, they might be appeased by its 15% dividend hike. No doubt that's the intent.
Investors skeptical of Teva chief's sales-growth plan
Options investors are betting against Teva Pharmaceutical Industries. And as Bloomberg reports, that fact doesn't surprise some analysts. Teva's new CEO, Jeremy Levin, unveiled his strategy last month--and that plan failed to quell shareholders' fears, they say.
Teva tries to slow arrival of Biogen's competing MS blockbuster
With $4 billion of Copaxone revenue on the line, it's no surprise to find Teva waving a red flag to the FDA as Biogen Idec gets down to the regulatory wire with its closely watched competitor BG-12. The big generics company filed a petition with the FDA demanding an advisory committee meeting to inspect what it has called potentially "serious safety risks."
Teva CEO says job cuts are small part of efficiency plans
Teva Pharmaceuticals ($TEVA) CEO Jeremy Levin is determined to persuade investors that the drugmaker is on the upswing these days. With some refocusing and restructuring, the generics giant can find a new path to the glories of yesteryear, Levin contended at the J.P. Morgan Healthcare Conference.
